Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.64 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.59 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.50 |
| ▸ | HNF4A | P41235 | 1/20 | 0.50 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | IDH1 | O75874 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | RGS12 | O14924 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL9783357 | 0.94 | AKR1B1 (0.57) | AKR1B1PLA2G10PLA2G2ALMNAGAA | |
| SCHEMBL70565 | 0.89 | AKR1B1 (0.71) | AKR1B1LMNAGAATSHRABCC4 | |
| Hydrochloric Acid SCHEMBL8922940 | 0.87 | AKR1B1 (0.68) | AKR1B1LMNAGAATSHRABCC4 | |
| Bromide SCHEMBL2068601 | 0.85 | PLA2G2A (0.54) | AKR1B1PLA2G10PLA2G2ALMNAGAA | |
| SCHEMBL11143386 | 0.85 | AKR1B1 (0.55) | AKR1B1PLA2G10PLA2G2ALMNAGAA | |
| SCHEMBL5696415 | 0.85 | AKR1B1 (0.81) | AKR1B1PLA2G10PLA2G2ALMNAGAA | |
| SCHEMBL7557354 | 0.84 | PLA2G2A (0.53) | PLA2G10PLA2G2ALMNAMTNR1AMTNR1B | |
| SCHEMBL4402323 | 0.83 | AKR1B1 (0.62) | AKR1B1LMNAGAATSHRABCC4 | |
| SCHEMBL9566231 | 0.82 | AKR1B1 (0.52) | AKR1B1PLA2G10PLA2G2ALMNAGAA | |
| SCHEMBL13971231 | 0.82 | CALM1 (0.75) | PLA2G10PLA2G2ALMNAMTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | NOVARTIS AG (CH) | 2009-04-23 | — | — | US | disclosed |
| EP-1309323-B1 | TREATMENT OF ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID DERIVATIVES | ALCON INC (CH) | 2006-11-15 | — | — | EP | disclosed |
| US-20050143468-A1 | Method of treating vascular endothelial growth factor mediated vascular disorders | ALCON, INC. (CH) | 2005-06-30 | — | — | US | disclosed |
| EP-1507522-A2 | METHOD OF TREATING VASCULAR ENDOTHELIAL GROWTH FACTOR MEDIATED VASCULAR DISORDERS USING AMFENAC OR NEPAFENAC | Alcon, Inc. (CH) | 2005-02-23 | — | — | EP | disclosed |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALCON, INC. (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2003092669-A2 | METHOD OF TREATING VASCULAR ENDOTHELIAL GROWTH FACTOR MEDIATED VASCULAR DISORDERS USING AMFENAC OR NEPAFENAC | ALCON, INC. (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-6646003-B2 | Topically administering to the eye of the patient a therapeutically effective amount of flurbiprofen amide derivative and ketorolac amide derivative to treat ophthalmic angiogenesis- related disorder of the posterior segment of eye | ALCON, INC. (CH) | 2003-11-11 | — | — | US | disclosed |
| US-20030207941-A1 | Method of treating vascular endothelial growth factor mediated vascular disorders | ALCON, INC. (CH) | 2003-11-06 | — | — | US | disclosed |
| US-6638976-B2 | 3-benzoylphenylacetic acids and derivatives, including nepafenac, to treat neurodegenerative retinal disorders | ALCON, INC. (CH) | 2003-10-28 | — | — | US | disclosed |
| US-20030187072-A1 | Method of treating angiogenesis-related disorders | ALCON, INC. (CH) | 2003-10-02 | — | — | US | disclosed |
| EP-1309322-A2 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS OF THE RETINA AND OPTIC NERVE HEAD | Alcon, Inc (CH) | 2003-05-14 | — | — | EP | disclosed |
| US-20020183376-A1 | Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac | ALCON, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2002078681-A2 | METHOD OF TREATING OCULAR INFLAMMATORY AND ANGIOGENESIS-RELATED DISORDERS USING AN AMIDE DERIVATIVE OF FLUBIPROFEN OR KETOROLAC | ALCON, INC. (CH) | 2002-10-10 | — | — | WO | disclosed |
| US-20020049255-A1 | Method of treating neurodegenerative disorders of the retina and optic nerve head | ALCON UNIVERSAL LTD. | 2002-04-25 | — | — | US | disclosed |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | ALCON UNIVERSAL LTD. | 2002-03-28 | — | — | US | disclosed |
| WO-2002013805-A2 | METHOD OF TREATING NEURODEGENERATIVE DISORDERS OF THE RETINA AND OPTIC NERVE HEAD | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002013804-A2 | METHOD OF TREATING ANGIOGENESIS-RELATED DISORDERS USING BENZOYL PHENYLACETIC ACID | ALCON, INC. (CH) | 2002-02-21 | — | — | WO | disclosed |
| CN-1314906-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-09-26 | — | — | CN | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183376-A1 | Method of treating ocular inflammatory and angiogenesis-related disorders of the posterior segment of the eye using an amide derivative of flurbiprofen or ketorolac | PTGIR, AADAC, PTGS1 | AKR1B1 41/4885PLA2G10 2724/4885PLA2G2A 1752/4885 |
| US-20020049255-A1 | Method of treating neurodegenerative disorders of the retina and optic nerve head | NLN, ALDH1A2, GAP43 | AKR1B1 1494/4885PLA2G10 1786/4885PLA2G2A 1166/4885 |
| US-20090105245-A1 | METHODS FOR TREATING MACULAR EDEMA AND OCULAR ANGIOGENESIS USING AN ANTI-INFLAMMATORY AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR | FLT1, TEK, FLT4 | AKR1B1 1522/4885PLA2G10 2452/4885PLA2G2A 1457/4885 |
| US-20040132773-A1 | Method of treating neurodgenerative disorders of the retina and optic nerve head | ALDH1A2, GAP43, NLN | AKR1B1 1556/4885PLA2G10 767/4885PLA2G2A 340/4885 |
| US-20020037929-A1 | Method of treating angiogenesis-related disorders | MME, FLT4, EYA3 | AKR1B1 1237/4885PLA2G10 3222/4885PLA2G2A 2506/4885 |
| US-20030187072-A1 | Method of treating angiogenesis-related disorders | MME, FLT4, EYA3 | AKR1B1 1237/4885PLA2G10 3222/4885PLA2G2A 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.